Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. In addition, Axsome intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. All of the shares in the offering are to be sold by Axsome.
Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes.
SVB Securities is acting as sole bookrunning manager for the offering.
The shares of common stock described above are being offered by Axsome pursuant to its previously filed shelf registration statement on Form S-3, which automatically became effective upon filing with the Securities and Exchange Commission. A preliminary prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC.
Interested to know about other companies in the same industry? Then please read –
KBI Biopharma appoints Jean-Baptiste Agnus as Chief Business Officer
InterAx Biotech Appoints Mark Levick, MD, Ph.D. As New DOB
Ligandal Inc. welcomes Tushar Nuwal as COO and CBO
